AGM and Board Update

Immupharma PLC 13 June 2007 For Immediate Release 13 June 2007 ImmuPharma PLC AGM Statement and Board Update ImmuPharma PLC (LSE:IMM), ('ImmuPharma' or the 'Company'), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were passed. Paddy Walker-Taylor, 60, currently part-time finance director, has decided by mutual agreement with the company to resign his role as director but remain with the company on a reduced-time basis. The Board wishes to thank Mr Walker-Taylor for his support during the early phase of the company and look forward to continuing working together. Dr. Robert Zimmer, MD, PhD, President & head of R&D, said 'we are delighted with the achievements in our R&D activities and in particular, the progress in the preparation of the phase II/III in the US and Europe, for which we hope to submit the file to the FDA in the next few weeks with the view of starting the phase II/III trial later this year.' For further information please contact: ImmuPharma PLC: Dimitri Dimitriou, Chief Executive +44 20 7152 4080 Officer Richard Warr, Chairman +44 20 7152 4080 Dr Robert Zimmer, President & Chief + 33 389 32 76 50 Scientific Officer Buchanan Communications + 44 20 7466 5000 Lisa Baderoon Rebecca Skye Dietrich Notes to Editors: About ImmuPharma ImmuPharma PLC is a drug discovery and development company headquartered in London, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It has research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases characterised by: * blockbuster potential in niche markets * low promotional costs in few specialised physicians and centres and * lower risk of drug development and lower development costs ImmuPharma is a currently developing drug candidates for three different medical conditions, each of which would represent a significant breakthrough in its field. The furthest advanced drug candidate targets Lupus, a disease for which there is currently no cure or specific treatment. The other two address moderate to severe pain (such as that experienced by cancer sufferers and post-operative patients), and MRSA and similar severe hospital-acquired resistant infections. All three have significant sales potential as well as low marketing costs and a relatively low risk of development failure. One or more have the potential to be fast-tracked by the US Food and Drug Administration according to 'Guidance for Industry: Fast Track Drug Development Programs - Designation, Development and Application Review' issued July 2004 and could therefore obtain their market authorization by 2010. Key to the potential success of ImmuPharma is its unique collaborative agreement with Centre National de la Recherche Scientifique, France's scientific research institution. This agreement grants ImmuPharma worldwide exclusive rights to exploit certain key discoveries. In addition to its three leading drug candidates, ImmuPharma has a drug development pipeline using its rights to a virtual chemical library of hundreds of thousands of molecules as well as an innovative technology for converting peptides to drug candidates. ImmuPharma has the option to commercialise its assets itself or to license them to other pharmaceutical companies at an earlier stage. The products Treatment of Lupus (IPP-201101) This is a long-term treatment for Lupus, a chronic, life-threatening autoimmune disease where the immune system attacks healthy cells. There is currently no cure and existing medications only treat the symptoms whereas ImmuPharma's drug candidate has the potential to produce remission of the disease in a substantial proportion of patients. Based on independent forecasts, the value of ImmuPharma's Lupus drug is estimated to be 'substantial' with peak annual sales forecast to generate in excess of $4 billion. Severe pain relief (IPP-102199) ImmuPharma is developing a potential non-addictive compound for relieving moderate to severe pain, such as experienced by cancer sufferers and post-surgical patients. Most existing treatments are derived from the opiate morphine and tend to have serious side effects. ImmuPharma's new treatment is based on met-enkephalin, the body's internal analgesic. IPP-102199 is being developed to have major advantages over morphine such as longer pain relief duration and reduced side effects. The market for chronic opioids in the US currently exceeds $3.5 billion and is growing by more than 10 to 20 per cent a year. Antibiotic for MRSA and similar highly resistant infections (IPP-203101) This is a novel antibiotic to combat MRSA and other severe hospital-acquired, resistant infections which affect some two million people in the US, according to the US Centers for Disease Control and Prevention. ImmuPharma's drug candidate is targeted at disrupting the membrane potential of the bacterial pathogens. It is hoped this novel approach will reduce their potential to become resistant. This information is provided by RNS The company news service from the London Stock Exchange

Companies

Immupharma (IMM)
UK 100

Latest directors dealings